Clinical Trial Update: Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia [Phase 3]

View source ↗

Summary

This document reports the completion of a Phase 3 long-term safety study evaluating Chronocort for congenital adrenal hyperplasia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Adrenal Hyperplasia

Drugs mentioned

• Chronocort

Snippet

Sponsor: Neurocrine UK Limited | Conditions: Congenital Adrenal Hyperplasia | Phase 3 | Status: COMPLETED